| Literature DB >> 32326426 |
Florence Carrouel1, Maria Pia Conte2, Julian Fisher3, Lucio Souza Gonçalves4, Claude Dussart5, Juan Carlos Llodra6, Denis Bourgeois1.
Abstract
Considered to be a major portal of entry for infectious agents, the oral cavity is directly associated with the evolutionary process of SARS-CoV-2 in its inhalation of ambient particles in the air and in expectorations. Some new generations of mouth rinses currently on the market have ingredients that could contribute to lower the SARS-CoV-2 viral load, and thus facilitate the fight against oral transmission. If chlorhexidine, a usual component of mouth rinse, is not efficient to kill SARS-CoV-2, the use of a mouth rinses and/or with local nasal applications that contain β-cyclodextrins combined with flavonoids agents, such as Citrox, could provide valuable adjunctive treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS-CoV-2 carriage. We urge national agencies and authorities to start clinical trials to evaluate the preventive effects of βCD-Citrox therapeutic oral biofilm rinses in reducing the viral load of the infection and possibly disease progression.Entities:
Keywords: 2019-nCoV; COVID-19; Citrox; SARS-CoV-2; microbiome; mouthrinse; oral cavity; viral load; β-cyclodextrins
Year: 2020 PMID: 32326426 PMCID: PMC7230644 DOI: 10.3390/jcm9041126
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241